mRNA vaccine development for cholangiocarcinoma: a precise pipeline

Tian-Yu Tang; Xing Huang; Gang Zhang; Ming-Hao Lu; Ting-Bo Liang

doi:10.1186/s40779-022-00399-8

Your Location：

Home >

Browse articles >

mRNA vaccine development for cholangiocarcinoma: a precise pipeline

PERSPECTIVE | Updated：2023-05-10

- mRNA vaccine development for cholangiocarcinoma: a precise pipeline
- mRNA vaccine development for cholangiocarcinoma: a precise pipeline
- Military Medical Research 2023年10卷第2期页码：262-267
- Affiliations：
  
  1.Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
  2.Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
  3.Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou 310003, China
  4.Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China
  5.Cancer Center, Zhejiang University, Hangzhou 310058, China
- Author bio：
  
  * huangxing66@zju.edu.cn;
  liangtingbo@zju.edu.cn
- Funds：
  
  the National Natural Science Foundation of China(31970696;81502975;81830089;U20A20378;82188102);Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholar(LR22H160010);National Key Research and Development Program of China(2019YFC1316000);Zhejiang Provincial Key Research and Development Program(2019C03019);Zhejiang Provincial College Student Science and Technology Innovation Activity Plan-College Student Innovation and Entre-preneurship Incubation Program (Young Talent Program)(2022R40122)
- DOI：10.1186/s40779-022-00399-8
  中图分类号：
- 纸质出版：2023-04
- Accepted：
Scan QR Code
mRNA vaccine development for cholangiocarcinoma: a precise pipeline[J]. Military Medical Research, 2023,10(2):262-267.

Cite this article as: Tang TY, Huang X, Zhang G, Lu MH, Liang TB. mRNA vaccine development for cholangiocarcinoma: a precise pipeline. Mil Med Res. 2022;9(1):40.
mRNA vaccine development for cholangiocarcinoma: a precise pipeline[J]. Military Medical Research, 2023,10(2):262-267. DOI： 10.1186/s40779-022-00399-8.

Cite this article as: Tang TY, Huang X, Zhang G, Lu MH, Liang TB. mRNA vaccine development for cholangiocarcinoma: a precise pipeline. Mil Med Res. 2022;9(1):40. DOI： 10.1186/s40779-022-00399-8.

摘要

Abstract

Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments

including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases

however

its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect

further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.

关键词

Keywords

references

Brindley PJ , Bachini M , Ilyas SI , Khan SA , Loukas A , Sirica AE , et al . Cholangiocarcinoma . Nat Rev Dis Primers. 2021 ; 7 ( 1 ): 65 .

Valle JW , Kelley RK , Nervi B , Oh DY , Zhu AX . Biliary tract cancer . Lancet. 2021 ; 397 ( 10272 ): 428 – 44 .

Rizvi S , Khan SA , Hallemeier CL , Kelley RK , Gores GJ . Cholangiocarcinoma—evolving concepts and therapeutic strategies . Nat Rev Clin Oncol. 2018 ; 15 ( 2 ): 95 – 111 .

Valle J , Wasan H , Palmer DH , Cunningham D , Anthoney A , Maraveyas A , et al . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer . N Engl J Med. 2010 ; 362 ( 14 ): 1273 – 81 .

Abou-Alfa GK , Macarulla T , Javle MM , Kelley RK , Lubner SJ , Adeva J , et al . Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebocontrolled, phase 3 study . Lancet Oncol. 2020 ; 21 ( 6 ): 796 – 807 .

Abou-Alfa GK , Sahai V , Hollebecque A , Vaccaro G , Melisi D , Al-Rajabi R , et al . Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study . Lancet Oncol. 2020 ; 21 ( 5 ): 671 – 84 .

Kelley RK , Bridgewater J , Gores GJ , Zhu AX . Systemic therapies for intrahepatic cholangiocarcinoma . J Hepatol. 2020 ; 72 ( 2 ): 353 – 63 .

Bridgewater J , Lopes A , Beare S , Duggan M , Lee D , Ricamara M , et al . A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study . BMC Cancer. 2016 ; 16 : 153 .

Pant S , Saleh M , Bendell J , Infante JR , Jones S , Kurkjian CD , et al . A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors . Ann Oncol. 2014 ; 25 ( 7 ): 1416 – 21 .

Postow MA , Callahan MK , Wolchok JD . Immune checkpoint blockade in cancer therapy . J Clin Oncol. 2015 ; 33 ( 17 ): 1974 – 82 .

Huang X , Tang T , Zhang G , Hong Z , Xu J , Yadav DK , et al . Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy . NPJ Precis Oncol. 2020 ; 4 ( 1 ): 29 .

Topalian SL , Hodi FS , Brahmer JR , Gettinger SN , Smith DC , McDermott DF , et al . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer . N Engl J Med. 2012 ; 366 ( 26 ): 2443 – 54 .

Klein O , Kee D , Nagrial A , Markman B , Underhill C , Michael M , et al . Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial . JAMA Oncol. 2020 ; 6 ( 9 ): 1405 – 9 .

Manne A , Woods E , Tsung A , Mittra A . Biliary tract cancers: treatment updates and future directions in the era of precision medicine and immuno-oncology . Front Oncol. 2021 ; 11 : 768009 .

Piha-Paul SA , Oh DY , Ueno M , Malka D , Chung HC , Nagrial A , et al . Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies . Int J Cancer. 2020 ; 147 ( 8 ): 2190 – 8 .

Jiang T , Shi T , Zhang H , Hu J , Song Y , Wei J , et al . Tumor neoantigens: from basic research to clinical applications . J Hematol Oncol. 2019 ; 12 ( 1 ): 93 .

Chen H , Yang M , Wang Q , Song F , Li X , Chen K . The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma . Oncoimmunology. 2019 ; 8 ( 8 ): 1608132 .

Rizvi NA , Hellmann MD , Snyder A , Kvistborg P , Makarov V , Havel JJ , et al . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer . Science. 2015 ; 348 ( 6230 ): 124 – 8 .

Schreiber RD , Old LJ , Smyth MJ . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion . Science. 2011 ; 331 ( 6024 ): 1565 – 70 .

Egeblad M , Werb Z . New functions for the matrix metalloproteinases in cancer progression . Nat Rev Cancer. 2002 ; 2 ( 3 ): 161 – 74 .

Jackson HW , Defamie V , Waterhouse P , Khokha R . TIMPs: versatile extracellular regulators in cancer . Nat Rev Cancer. 2017 ; 17 ( 1 ): 38 – 53 .

Tang T , Huang X , Zhang G , Hong Z , Bai X , Liang T . Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy . Signal Transduct Target Ther. 2021 ; 6 ( 1 ): 72 .

Kubli SP , Berger T , Araujo DV , Siu LL , Mak TW . Beyond immune checkpoint blockade: emerging immunological strategies . Nat Rev Drug Discov. 2021 ; 20 ( 12 ): 899 – 919 .

Blass E , Ott PA . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines . Nat Rev Clin Oncol. 2021 ; 18 ( 4 ): 215 – 29 .

Koido S , Homma S , Okamoto M , Takakura K , Mori M , Yoshizaki S , et al . Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer . Clin Cancer Res. 2014 ; 20 ( 16 ): 4228 – 39 .

Shimizu K , Kotera Y , Aruga A , Takeshita N , Takasaki K , Yamamoto M . Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma . J Hepatobiliary Pancreat Sci. 2012 ; 19 ( 2 ): 171 – 8 .

Löfffler MW , Chandran PA , Laske K , Schroeder C , Bonzheim I , Walzer M , et al . Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient . J Hepatol. 2016 ; 65 ( 4 ): 849 – 55 .

Saxena M , van der Burg SH , Melief CJM , Bhardwaj N . Therapeutic cancer vaccines . Nat Rev Cancer. 2021 ; 21 ( 6 ): 360 – 78 .

Alexopoulou L , Holt AC , Medzhitov R , Flavell RA . Recognition of doublestranded RNA and activation of NF-kappaB by Toll-like receptor 3 . Nature. 2001 ; 413 ( 6857 ): 732 – 8 .

Heil F , Hemmi H , Hochrein H , Ampenberger F , Kirschning C , Akira S , et al . Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 . Science. 2004 ; 303 ( 5663 ): 1526 – 9 .

Kowalczyk A , Doener F , Zanzinger K , Noth J , Baumhof P , Fotin-Mleczek M , et al . Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity . Vaccine. 2016 ; 34 ( 33 ): 3882 – 93 .

Edwards DK , Jasny E , Yoon H , Horscroft N , Schanen B , Geter T , et al . Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response . J Transl Med. 2017 ; 15 ( 1 ): 1 .

Sahin U , Türeci Ö . Personalized vaccines for cancer immunotherapy . Science. 2018 ; 359 ( 6382 ): 1355 – 60 .

Heine A , Juranek S , Brossart P . Clinical and immunological effects of mRNA vaccines in malignant diseases . Mol Cancer. 2021 ; 20 ( 1 ): 52 .

Van Tendeloo VF , van de Velde A , van Driessche A , Cools N , Anguille S , Ladell K , et al . Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination . Proc Natl Acad Sci U S A. 2010 ; 107 ( 31 ): 13824 – 9 .

Lesterhuis WJ , de Vries IJ , Schreibelt G , Schuurhuis DH , Aarntzen EH , De Boer A , et al . Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients . Anticancer Res. 2010 ; 30 ( 12 ): 5091 – 7 .

Amin A , Dudek AZ , Logan TF , Lance RS , Holzbeierlein JM , Knox JJ , et al . Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results . J Immunother Cancer. 2015 ; 3 : 14 .

Sahin U , Oehm P , Derhovanessian E , Jabulowsky RA , Vormehr M , Gold M , et al . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma . Nature. 2020 ; 585 ( 7823 ): 107 – 12 .

Kyte JA , Aamdal S , Dueland S , Saeboe-Larsen S , Inderberg EM , Madsbu UE , et al . Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells . Oncoimmunology. 2016 ; 5 ( 11 ): e1232237 .

Bol KF , Figdor CG , Aarntzen EH , Welzen ME , van Rossum MM , Blokx WA , et al . Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients . Oncoimmunology. 2015 ; 4 ( 8 ): e1019197 .

Weide B , Pascolo S , Scheel B , Derhovanessian E , Pflugfelder A , Eigentler TK , et al . Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients . J Immunother. 2009 ; 32 ( 5 ): 498 – 507 .

Khoury HJ , Collins RH , Blum W , Stiff PS , Elias L , Lebkowski JS , et al . Immune responses and long-term disease recurrence status after telomerasebased dendritic cell immunotherapy in patients with acute myeloid leukemia . Cancer. 2017 ; 123 ( 16 ): 3061 – 72 .

Gao J , Aksoy BA , Dogrusoz U , Dresdner G , Gross B , Sumer SO , et al . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal . Sci Signal. 2013 ; 6 ( 269 ): l1 .

Tang Z , Li C , Kang B , Gao G , Li C , Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses . Nucleic Acids Res. 2017 ; 45 ( W1 ): W98 - 102 .

Li T , Fan J , Wang B , Traugh N , Chen Q , Liu JS , et al . TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells . Cancer Res. 2017 ; 77 ( 21 ): e108 – 10 .

Huang X , Tang T , Zhang G , Liang T . Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development . Mol Cancer. 2021 ; 20 : 50 .

Roudko V , Greenbaum B , Bhardwaj N . Computational prediction and validation of tumor-associated neoantigens . Front Immunol. 2020 ; 11 : 27 .

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine

MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies

Role of the immune microenvironment in bone, cartilage, and soft tissue regeneration: from mechanism to therapeutic opportunity

基于ANSYS的EP电磁阀静态性能仿真分析

开裂预应力混凝土梁的检测、评估和加固